Related Experiment Videos
Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis
I Goldstein1, M Topilsky, D Segev
1Department of Internal Medicine II, Tel Aviv Medical Center, Israel.
Chest
|May 1, 1997
Abstract:
A case of amiodarone pulmonary toxicity (APT) occurring within days of the start of therapy and presenting with hemoptysis is reported. Both the very early onset and the presenting symptom are highly unusual in this entity. Implications in the diagnosis of APT are discussed.
Insights
A rare case of amiodarone pulmonary toxicity occurred days after starting medication, presenting unusually with hemoptysis. This early onset and symptom presentation offer new insights into diagnosing amiodarone pulmonary toxicity.
Area of Science:
- Pulmonology
- Cardiology
- Pharmacology
Background:
- Amiodarone is a widely used antiarrhythmic drug.
- Pulmonary toxicity is a known but infrequent adverse effect of amiodarone therapy.
- The onset and presentation of amiodarone pulmonary toxicity can vary significantly.
Observation:
- A patient developed symptoms of amiodarone pulmonary toxicity within days of initiating amiodarone therapy.
- The patient presented with hemoptysis, an uncommon initial symptom for APT.
- This presentation is highly unusual for the typical timeline and symptoms of APT.
Findings:
- The rapid onset of APT challenges the conventional understanding of its temporal relationship with amiodarone exposure.
- Hemoptysis as a primary symptom in this early-onset case is atypical for amiodarone pulmonary toxicity.
- The case underscores the variability in APT presentation.
Implications:
- Early recognition of APT is crucial, even with short-term amiodarone use.
- Clinicians should consider APT in patients with hemoptysis shortly after starting amiodarone.
- This case broadens the diagnostic spectrum for amiodarone-induced lung injury.